Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis Patients

Authors

  • Ayesha Jamil Department of Pharmacology, Khyber Girls Medical College, Peshawar - Pakistan
  • Nighat Aziz Department of Pharmacology, Gomal medical college, Dera Ismail Khan - Pakistan
  • Ikram Zada Department of Gastroenterology, F.G Polyclinic Hospital, Islamabad - Pakistan
  • Ali Ghias Tarar District Head Quarter Hospital, Mandi Bahaudin - Pakistan
  • Jawad Hussain Qamber Department of Physiology, Sahara Medical College, Narowal - Pakistan
  • Muhammad Usman Sheikh Department of Community Medicine, Avicenna Medical College, Lahore - Pakistan

Keywords:

Pulmonary Diseases, DR-TB, Treatment Supporters

Abstract

Background:Drug-resistant tuberculosis (DR-TB) presents significant challenges to treatment success, necessitating effective support systems. Objective: To explore the impact of treatment supporters on the outcomes of drug-resistant tuberculosis (DR-TB) patients. Methodology: A retrospective cohort study was conducted involving 300 DR-TB patients, categorized by their treatment supporters, i.e. family members, and community health workers. Treatment outcomes were analyzed, including cure rates, treatment completion, mortality, treatment failure, and loss to follow-up. All data were entered into SPSS for final analysis. Results:Of 300 treatment supporters, 63.7% were female, mostly aged 31-40. Treatment success was higher (44.3%) with family members as supporters, compared to 4.4% with non-family supporters. Among 265 drug-resistant tuberculosis (DR-TB) patients studied, 62.26% were male, and the most affected age group was 21-40 years (54.72%). Between 2017 and 2021, 41.5% completed treatment, 10.19% were cured, 18.87% died, and 11.7% each faced treatment failure or were lost to follow-up. Conclusion:This study highlights the critical role of treatment supporters in enhancing adherence and improving recovery rates for DR-TB patients. The results underscore the importance of integrating effective treatment support programs into DR-TB management strategies. By optimizing the roles of various treatment supporters and addressing their challenges, healthcare systems can improve treatment success and contribute to broader public health efforts against tuberculosis.

References

Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I, et al. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. Saudi Med J. 2015;36(12):1463.

Khan MA, Aziz A, Ullah U, Ullah N, Jan F, Nasir SM, et al. Treatment outcomes of short-course regimens for multidrug-resistant tuberculosis patients in Peshawar. Pak J Chest Med. 2020;26(4):210-6.

World Health Organization. Prioritization of pathogens to guide discovery, research, and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. World Health Organization; 2017.

Khanal S, Elsey H, King R, Baral SC, Bhatta BR, Newell JN. Development of a patient-centered, psychosocial support intervention for multi-drug-resistant tuberculosis (MDR-TB) care in Nepal. PloS one. 2017;12(1):e0167559.

Nachega JB, Knowlton AR, Deluca A, Schoeman JH, Watkinson L, Efron A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study. J Acquir Immune Defic Syndr. 2006;43

Giri OP, Kumar A, Giri VP, Nikhil N. Impact of treatment supporters on the treatment outcomes of drug-resistant tuberculosis (DR-TB) patients: a retrospective cohort study. Cureus. 2022;14(3).

Snyman L, Venables E, Trivino Duran L, Mohr E, Azevedo VD, Harmans X, et al. ‘I didn't know so many people cared about me': supporting patients who interrupt drug-resistant TB treatment. Int J Tuberc Lung Dis. 2018;22(9):1023-30.

Khan MA, Javiad A, Basit A, Adnan MA, Ahmad F, Khan N, et al. Community-based management of multidrug-resistant tuberculosis (MDR-TB) in the population of Khyber Pakhtunkhwa. Pak J Chest Med. 2015;21(4):134-8.

Adejumo OA, Daniel OJ, Otesanya AF, Ashipa T, Adejumo EN, Abdur-Razzaq HA. Factors affecting treatment interruption among TB patients in Lagos, Nigeria: is there any need for treatment supporters? Int J Clin Med. 2016;7(06):389-98.

World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization; 2019.

Nirmal A, Kuzmik A, Sznajder K, Lengerich E, Fredrick NB, Chen M, et al. ‘If not for this support, I would have left the treatment!': Qualitative study exploring the role of social support on medication adherence among pulmonary tuberculosis patients in Western India. Glob Public Health. 2022;17(9):1945-57.

Kumar D, Goel C, Bansal AK, Bhardwaj AK. Delineating the factors associated with recurrence of tuberculosis in programmatic settings of rural health block, Himachal Pradesh, India. Indian J Tuberc. 2018;65(4):303-7.

Nachega JB, Kapata N, Sam-Agudu NA, Decloedt EH, Katoto PD, Nagu T, et al. Minimizing the impact of the triple burden of COVID-19, tuberculosis, and HIV on health services in sub-Saharan Africa. Int J Infect Dis. 2021;113

Rajendran M, Zaki RA, Aghamohammadi N. Contributing risk factors towards the prevalence of multidrug-resistant tuberculosis in Malaysia: A systematic review. Tuberculosis. 2020;122:101925.

Kung’u M, Onsongo L, Ogutu JO. Factors influencing quality of life among cancer survivors in Kenya. Afr Health Sci. 2022;22(4):87-95.

Downloads

Published

2023-06-02

How to Cite

Jamil, A., Aziz, N., Zada, I., Tarar, A. G., Qamber, J. H., & Sheikh, M. U. (2023). Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis Patients. Pakistan Journal of Chest Medicine, 29(2), 237–242. Retrieved from https://pjcm.net/index.php/pjcm/article/view/903

Issue

Section

Original Article

Most read articles by the same author(s)